美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective to investigate the clinical effect of Metoprolol combined with Trimetazidine on the treatment of coronary heart disease with heart failure.Methods A total of 100 patients with coronary heart disease and heart failure who admitted to Hongqi Hospital Affiliated to Mudanjiang Medical University from February 2017 to February 2018 were selected as the research objects and divided into the study group and the control group according to the random number table method,with 50 cases in each group.The observation group was treated with Metoprolol combined with Trimetazidine,the control group was treated with routine treatment.The cardiac function indexes and clinical effect were compared between the two groups..Results Before treatment,there were no statistically significant differences in heart rate (HR),left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) between the two groups (P>0.05).After treatment,the HR,LVESD,LVEDD in the study group were lower than those in the control group,the LVEF was higher than that in the control group,and the differences were statistically significant (P<0.05).After treatment,the HR,LVESD,LVEDD in the two groups were lower than those before treatment,the LVEF was higher than that before treatment,and the differences were statistically significant(P<0.05).The total effective rate of the study group (96.00%[48/50]) was higher than that of the control group (76.00%[38/50]),and the difference was statistically significant (P<0.05).Conclusion The treatment of Metoprolol combined with Trimetazidine in patients with coronary heart disease and heart failure can effectively improve the cardiac function of patients,and achieve very significant clinical effect,which is worthy of clinical promotion and application.

Key words： Metoprolol Trimetazidine Coronary heart disease Heart failure Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Kai
	WANG Xin-wei
	GAO Yu-qiu

Cite this article:

ZHANG Kai,WANG Xin-wei,GAO Yu-qiu. Clinical effect of Metoprolol combined with Trimetazidine in the treatment of coronary heart disease with heart failure[J]. 中国当代医药, 2020, 27(36): 145-147.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I36/145

[1]	宋一平，曹爱红.稳心颗粒联合美托洛尔治疗老年冠心病心律失常的效果[J].中国卫生标准管理，2018，9（19）：124-126.
[2]	梁国君，廖桂华.普伐他汀联合美托洛尔治疗冠心病心力衰竭的临床研究[J].现代药物与临床，2018，33（8）：1932-1935.
[3]	秦全国.美托洛尔在治疗糖尿病合并冠心病的临床效果分析[J].实用糖尿病杂志，2018，14（1）：33-34.
[4]	蔡新强.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果研究[J].吉林医学，2018，39（1）：120-122.
[5]	李翠芝，潘越峻，张文先，等.缬沙坦联合美托洛尔对冠心病患者血液流变学研究[J].心血管外科杂志（电子版），2018，7（2）：201-202.
[6]	迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息，2018，31（3）：139-141.
[7]	顾红莲.美托洛尔联合稳心颗粒治疗冠心病心律失常的临床观察[J].中西医结合心血管病杂志（电子版），2018，6（19）：1-2.
[8]	窦丹燕.法舒地尔联合曲美他嗪对心力衰竭患者的临床研究[J].中国临床药理学杂志，2019，34（18）：1976-1978.
[9]	蒋端，李静.多重用药对冠心病患者发生氯吡格雷抵抗的影响研究[J].中国全科医学，2019，21（30）：3709-3713.
[10]	杨志栋.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果观察[J].临床医药文献电子杂志，2019，5（21）：68.
[11]	赵丽花.琥珀酸美托洛尔缓释片联合曲美他嗪治疗冠心病心绞痛疗效观察[J].中西医结合心血管病杂志（电子版），2019，7（17）：39，42.
[12]	纪东华.曲美他嗪治疗老年冠心病心力衰竭的疗效及其对患者炎症因子的影响[J].医学信息，2019，32（13）：141-142.
[13]	商智杰.美托洛尔联合曲美他嗪治疗冠状动脉性心脏病心力衰竭患者临床疗效观察[J].名医，2018，8（2）：4，16.
[14]	韩庭伟，武占玮.芪苈强心胶囊联合曲美他嗪治疗气虚血瘀型慢性肺源性心脏病60例[J].西部中医药，2019，32（8）：95-97.
[15]	李小影，钱江洁，潘景业.血液透析联合美托洛尔治疗尿毒症合并急性左心衰竭的疗效及对心肌酶谱变化的影响[J].数理医药学杂志，2018，30（1）：55-58.
[16]	谢盛.美托洛尔联合曲美他嗪对冠心病心力衰竭患者心脏功能的影响分析[J].中国医药科学，2020，10（6）：76-78，103.
[17]	张邻川，钟琳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].中国现代医生，2019，57（33）：50-52.
[18]	王世杰，张炎.冠心病慢性心力衰竭行贝那普利联合曲美他嗪治疗效果及心功能指标分析[J].泰山医学院学报，2018，39（8）：870-872.